Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024

Description:
Antibody drug conjugates (ADCs) are a new class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies. Generally addressed as the marriage of an antibody with a toxic drug / chemotherapy drug, these conjugates are believed to be more efficient and effective in the treatment of a disease.

The ADC market is still in its infancy. At present, Adcetris and Kadcyla are the only two marketed drugs. However, there are several ADCs under development, with most of them being developed for oncological indication. Pharmaceutical companies are keen to add innovative molecules to their diminishing product pipelines and ADCs provide an attractive opportunity due to their novel nature.

Although the market now has presence of several large pharmaceutical companies, the technological capabilities for development of ADC still lies with a few technology providers. Seattle Genetics and ImmunoGen are amongst the pioneers in the field of ADC, with most pipeline ADCs using their technology. Most development to date has been carried under technology license agreements. However, we expect to see more co-development agreements in the future.

As more ADCs move from pipeline to the market, there is likely to be a further increase in investments in this area. Drug developers / venture capital firms are investing huge amount of money in biologics and it remains to be seen what proportion of this will be directed towards ADCs. The current market landscape will gradually evolve as large pharmaceutical companies look to gain competitive advantage in the ADC market. The future of the market is promising, though there are several challenges to meet.

The Antibody Drug Conjugates Market (2nd edition), 2014-2024 report provides an extensive study on this emerging field of therapeutics. The report covers various aspects, such as, advantages of antibody drug conjugates over traditional antibody therapeutics, the need for this new class of medicine, manufacturing challenges, key market drivers and upcoming opportunities.

One of the key objectives of this report is to understand the current and future state of the antibody drug conjugates market. This is done by analysing:

- Products currently available in the market and those under development (both clinical / pre-clinical),
- Technology providers, and key cytotoxin, linker and conjugation technologies supporting the development of improved ADCs,
- Partnerships which have taken place over the last five years covering product co-development, technology licensing and co-marketing,
- Competitive landscape and inherent threats to growth in the short and long term,
- Development and sales potential based on target consumer segments, likely adoption rate and expected pricing.

The base year for the report is 2013; actual sales data has been presented for marketed ADCs during this year. The report provides short-mid term and long term market forecasts for the period 2014 - 2019 and 2019 - 2024, respectively. The research, analysis and insights presented in this report include potential sales of 11 marketed and pipeline ADCs; this analysis is backed by a deep understanding of key drivers behind the growth.

Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.

All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. The Traditional Treatments: Naked Antibody and Cytotoxins
3.2.1. Naked Antibodies
3.2.1.1. How Monoclonal Antibody Therapy Works
3.2.2. Cytotoxins
3.3. Conjugated or Armed Antibodies
3.4. The Revolutionary Technology: ADCs
3.5. Advantages of ADC over Traditional Therapeutics
3.6. Parts of an ADC
3.6.1. Antibody
3.6.2. Cytotoxin
3.6.3. Linker: Function and Types

4. ADC THERAPEUTICS: OVERVIEW AND BACKGROUND
4.1. Chapter Overview
4.2. Kadcyla Becomes the Third ADC to Reach Market
4.2.1. Mylotarg (Pfizer)
4.2.1.1. Mechanism of Action
4.2.1.2. Approval and Discontinuation of Mylotarg in the US
4.2.1.3. Reasons for Poor Clinical Benefits of Mylotarg
4.2.2. Adcetris (Seattle Genetics/Takeda Oncology Company)
4.2.3. Kadcyla (Roche/Genentech)
4.3. Companies Active in the ADC Market
4.3.1. Large Pharmaceutical Companies Taking Interest
4.4. Companies Providing ADC Technology
4.5. Role of Venture Capitalists
4.6. Analysis of the Development Pipeline
4.6.1. Limited Number of Molecules in Late Stage Development
4.6.2. Cancer is the Leading Indication, with ADCs Against Blood Cancer Dominating
4.7. Commonly Used Cytotoxins in ADC
4.7.1. Cytotoxins Used in ADCs are Highly Potent APIs
4.7.2. Auristatins are the Most Commonly Used Cytotoxins
4.8. Linker: Function and Types
4.8.1. Manufacturing of Linkers
4.8.2. ADC Market by Type of Linker

5. ADC MARKET FORECAST, 2014 - 2024
5.1. Chapter Overview
5.2. ADC Market, 2013
5.2.1. Adcetris and Kadcyla were the Sole Participant in the Market in 2013
5.3. Overall ADC Market Forecast, 2014-2024
5.3.1. Scope and Limitations
5.3.2. Forecast Methodology
5.3.3. The ADC Drug Sales Market, 2014 - 2024
5.3.3.1. Overall Sales Forecast, 2014 - 2024: By Type of ADC
5.3.3.2. Overall Sales Forecast, 2014 - 2024: By Type of Linker
5.3.3.3. Overall Sales Forecast, 2014 - 2024: By Type of Cytotoxin
5.4. Adcetris (Seattle Genetics / Millennium)
5.4.1. Mechanism of Action
5.4.2. The Cost of Treatment with Adcetris and Reimbursement
5.4.3. Factors Supporting the High Price
5.4.4. Adcetris Sales, 2011-Q1 2014
5.4.5. Strategies for Market Expansion
5.4.6. Adcetris Sales Forecast: Short-Mid Term, 2014-2019
5.4.7. Adcetris Sales Forecast: Long Term, 2019-2024

5.5. Kadcyla / T-DM1 (Genentech / Roche)
5.5.1. Drug Specifications
5.5.2. Launch and Reimbursement
5.5.3. Pricing
5.5.4. Roche’s Survival Kit
5.5.5. Long Route to Approval
5.5.6. Kadcyla Sales
5.5.7. Current State of Development: Indications and Timeline
5.5.8. Kadcyla Sales Forecast, 2014-2019
5.5.9. Kadcyla Sales Forecast: Long Term, 2019-2024

5.6. Glembatumumab Vedotin / CDX-011 (Celldex Therapeutics)
5.6.1. The Drug Specifications
5.6.2. Clinical Development
5.6.2.1. Metric Trial
5.6.3. Competition for CDX-011
5.6.4. CDX-011 Sales Forecast, 2014-2019
5.6.5. CDX-011 Sales Forecast: Long Term, 2019-2024

5.7. BT-062 (Biotest)
5.7.1. Drug Specifications
5.7.2. Clinical Development
5.7.3. Competition for BT-062
5.7.4. BT-062 Sales Forecast: Short-Mid Term, 2017-2019
5.7.5. BT-062 Sales Forecast: Long Term, 2019-2024

5.8. Inotuzumab Ozogamicin/CMC-544 (Pfizer)
5.8.1. Drug Specifications
5.8.2. Current Development Status
5.8.3. Competition for CMC-544
5.8.4. Inotuzumab Ozogamicin / CMC-544 Sales Forecast: Long Term, 2018-2024

5.9. RG7593 and RG7596 (Roche)
5.9.1. Drug Specifications
5.9.2. Clinical Development
5.9.3. Future Plans
5.9.4. RG7596 Sales Forecast: Long Term, 2018-2024
5.10. PSMA-ADC (Progenics)
5.10.1. Drug Specifications
5.10.2. PSMA ADC Development for Prostate Cancer
5.10.3. Competition for PSMA ADC
5.10.4. PSMA ADC Sales Forecast: Long Term, 2019-2024

5.11. SAR3419 (Sanofi Aventis)
5.11.1. Drug Specifications
5.11.2. Structure, Administration and Dosage
5.11.3. Current State of Development
5.11.4. Competition for SAR3419
5.11.5. SAR3419 Sales Forecast: Long Term, 2019-2024

5.12. IMMU-130 (Immunomedics)
5.12.1. Drug Specifications
5.12.2. Clinical Development
5.12.3. Competition for IMMU-130
5.12.4. IMMU-130 Sales Forecast: Long Term, 2019-2024

5.13. RG7599 (Roche / Genentech)
5.13.1. Drug Specifications
5.13.2. Clinical Trial and Development
5.13.3. Competition For RG7599
5.13.4. RG7599 Sales Forecast: Long Term, 2020-2024
5.14. ABT-414 (AbbVie)
5.14.1. Drug Specifications
5.14.2. Clinical Trials and Development
5.14.3. Competition for ABT-414
5.14.4. ABT-414 Sales Forecast: Long Term, 2020-2024

6. MANUFACTURING OF ADCs
6.1. Chapter Overview
6.2. Steps Involved in Manufacturing an ADC
6.3. Challenges Facing the ADC Manufacturers
6.4. In-House Manufacturing of ADCs
6.5. Presence of Contract Manufacturers
6.5.1. Linkers
6.5.2. Cytotoxins
6.5.3. Conjugation
6.6. Leading ADC Contract Manufacturers
6.6.1. SAFC
6.6.2. Piramal Healthcare
6.6.3. Lonza
6.6.4. Albany Molecular Research Institute (AMRI)
6.6.5. BSP Pharmaceuticals
6.6.6. Pierre Fabre Medicament Production (PFMP)
6.6.7. Catalent
6.7. CMOs Investing in ADC Capabilities
6.8. Contract Manufacturers Collaborating to Provide ADC Capabilities

7. RECENT DEVELOPMENTS: FOCUS ON PARTNERSHIPS AND TECHNOLOGY EVOLUTION
7.1. Chapter Overview
7.2. Recent Partnerships
7.2.1. Partnership Models
7.2.2. Number of Partnerships have Increased Overtime
7.2.3. Seattle Genetics and ImmunoGen have been the Most Active Companies
7.3. Technological Developments
7.3.1. Emerging Cytotoxins/Payload
7.3.2. Linker Technologies
7.3.3. Site-Specific Conjugation Technology
7.3.4. Use of Antibody Fragments in Place of Whole Antibody

8. PROFILES OF LEADING COMPANIES
8.1. Chapter Overview
8.2. ImmunoGen
8.2.1. Targeted Antibody Payload (TAP) Technology
8.2.1.1. Linker Technology
8.2.2. Marketed and Pipeline Products
8.2.2.1. Marketed ADCs
8.2.2.2. Pipeline ADCs
8.2.3. Business Model
8.2.3.1. Types of Agreements and Current Partners
8.2.4. Marketed and Pipeline Products
8.2.4.1. Marketed ADCs
8.2.5. Financial Performance

8.3. Seattle Genetics
8.3.1. ADC Technology
8.3.2. Exploring New Technologies
8.3.2.1. Novel Cytotoxins
8.3.2.2. Site-Specific Conjugation Technology
8.3.3. Business Model
8.3.3.1. Types of Agreements and Current Partners
8.3.4. Marketed and Pipeline Products
8.3.4.1. Marketed ADCs
8.3.4.2. Pipeline ADCs
8.3.5. Financial Performance
8.4. Immunomedics
8.4.1. Marketed and Pipeline Products
8.4.2. Financial Performance

8.5. Spirogen (Acquired by MedImmune)
8.5.1. Pyrrolobenzodiazepines (PBDs) Technology
8.5.2. ADC Development and Collaborations
8.5.3. AstraZeneca Takes Over Spirogen

8.6. Pfizer
8.6.1. Marketed and Pipeline Products
8.6.2. Collaboration with Seattle Genetics
8.6.3. Financial Performance

8.7. Roche/Genentech
8.7.1. Evaluating Technology from ImmunoGen and Seattle Genetics
8.7.2. Development Pipeline: 10 Molecules in Clinical Development
8.7.3. Financial Performance

8.8. Polytherics (An Abzena Company)
8.8.1. ThioBridge Technology
8.8.2. Pegylation and Optimisation Technology
8.8.3. Business Model
8.8.4. Revenue Generation

8.9. Oxford BioTherapeutics
8.9.1. Oxford Genome Anatomy Project
8.9.2. ADC Pipeline

8.10. Other Companies
8.10.1. Mersana Therapeutics
8.10.1.1. Fleximer- ADC Technology
8.10.1.2. ADC Collaborations
8.10.1.3. Funding

8.10.2. Synthon
8.10.2.1. ADC Technology
8.10.2.2. ADC Manufacturing
8.10.2.3. ADC Pipeline

8.10.3. Intellect Neurosciences
8.10.3.1. CONJUMAB-A Technology
8.10.3.2. ADC Pipeline
8.10.3.3. Financial Performance

8.10.4. Progenics Pharmaceuticals
8.10.4.1. PSMA Targeted Oncology Pipeline
8.10.4.2. Financial Performance

8.10.5. Astellas Pharma/Agensys
8.10.5.1. ADC Pipeline
8.10.5.2. Financial Performance

8.10.6. Heidelberg Pharma
8.10.6.1. ADC Technology
8.10.6.2. ADC Pipeline

9. SWOT ANALYSIS
9.1. Strengths
9.2. Weaknesses
9.3. Opportunities
9.4. Threats
10. INTERVIEW TRANSCRIPTS
10.1. Interview 1: Lonza, Laurent Ducry, ADC R&D
10.2. Interview 2: Polytherics (an Abzena company), Dr. John Burt, CEO, Abzena
10.3. Interview 3: Oxford BioTherapeutics, Dr. Christian Rohlf, Founder and CEO
10.4. Interview 4: Catalent Pharma Solutions, Stacy McDonald, Group Product Manager & Jennifer L. Mitcham, Director - Business Development
10.5. Interview 5: BSP Pharmaceuticals, Aldo Braca, CEO
10.6. Interview 6: Piramal Healthcare, Dr. Mark Wright, Site Head, Grangemouth
10.7. Interview 7: Leading CMO, Director, Business Development

11. CONCLUSIONS
11.1. ADC: Expanding the Pipeline of Biologics
11.2. Market is in its Infancy, with Huge Potential for Growth
11.3. CMOs: Narrowing the Need Supply Gap
11.4. An Attractive Market for Large Pharmaceutical Companies
11.5. Concluding Remarks

12. APPENDIX 1: TABLES

13. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

List of Figures:

Figure 2.1 ADC Clinical Trials: Market Map
Figure 3.1 Parts of Antibody Drug Conjugate
Figure 4.1 Companies Active in the ADC Market: Number of Molecules in Development (Clinical and Marketed)
Figure 4.2 ADCs in Clinical Development: Share (%) by Phase of Development
Figure 5.1 ADC Sales Forecast, 2014 - 2024: Base Scenario (USD Million)
Figure 5.2 ADC Sales Forecast, 2014 - 2024: By Type of ADC (USD Million)
Figure 5.3 ADC Sales Forecast, 2014 - 2024: By Type of Linker (USD Million)
Figure 5.4 ADC Sales Forecast, 2014 - 2024: By Type of Cytotoxin (USD Million)
Figure 5.5 Adcetris Sales, 2011-Q1 2014 (USD Million)
Figure 5.6 Adcetris Market (USD Million), Short-Midterm Forecast: 2014-2019 (Base Scenario)
Figure 5.7 Adcetris Market (USD Million), Long Term Forecast: 2019-2024 (Base Scenario)
Figure 5.8 Kadcyla Sales, 2013 - 2014 (USD Million)
Figure 5.9 Kadcyla / T-DM1 Market (USD Million), Short-Midterm Forecast: 2014-2019 (Base Scenario)
Figure 5.10 Kadcyla / T-DM1 Market (USD Million), Long Term Forecast: 2019-2024 (Base Scenario)
Figure 5.11 Glembatumumab Vedotin / CDX-011 Market (USD Million), Short-Midterm Forecast: 2017-2019 (Base Scenario)
Figure 5.12 Glembatumumab Vedotin / CDX-011 Market (USD Million), Long Term Forecast: 2019-2024 (Base Scenario)
Figure 5.13 BT-062 Market (USD Million), Short-Midterm Forecast, 2017-2019 (Base Scenario)
Figure 5.14 BT-062 Market (USD Million), Long Term Forecast, 2019-2024 (Base Scenario)
Figure 5.15 Inotuzumab Ozogamicin / CMC-544 Market (USD Million), Long Term Forecast: 2018-2024 (Base Scenario)
Figure 5.16 RG7596 Market (USD Million), Long Term Forecast, 2018-2024 (Base Scenario)
Figure 5.17 PSMA ADC Market (USD Million), Long Term Forecast, 2019-2024 (Base Scenario)
Figure 5.18 SAR3419 Market (USD Million), Long Term Forecast, 2019-2024 (Base Scenario)
Figure 5.19 IMMU-130 Market (USD Million), Long Term Forecast, 2018-2024 (Base Scenario)
Figure 5.20 RG7599 Market (USD Million), Long Term Forecast, 2018-2024 (Base Scenario)
Figure 5.21 ABT-414 Market (USD Million), Long Term Forecast, 2018-2024 (Base Scenario)
Figure 7.1 Number of Partnerships in the Field of ADCs, 2005 - 2014
Figure 7.2 ADC Partnerships: Major Stakeholders

List of Tables:
Table 3.1 Commonly Used Cytotoxins for ADC Therapeutics
Table 4.1 Approval History of Mylotarg
Table 4.2 ADC Molecules in Clinical Development: Roche / Genentech
Table 4.3 ADC Molecules in Clinical Development: Seattle Genetics
Table 4.4 ADC Molecules in Clinical Development: ImmunoGen
Table 4.5 ADC Molecules in Clinical Development: Immunomedics
Table 4.6 ADC Molecules in Clinical Development: Astellas Pharma / Agensys
Table 4.7 ADC Molecules in Clinical Development: Pfizer / Wyeth
Table 4.8 ADC Molecules in Clinical Development: Sanofi Aventis
Table 4.9 ADC Molecules in Clinical Development: Amgen
Table 4.10 ADC Molecules in Clinical Development: AbbVie
Table 4.11 ADC Molecules in Clinical Development: Millennium
Table 4.12 ADC Molecules in Clinical Development: Celldex Therapeutics
Table 4.13 ADC Molecules in Clinical Development: Progenics Pharmaceuticals
Table 4.14 ADC Molecules in Clinical Development: Genmab
Table 4.15 ADC Molecules in Clinical Development: Bayer Healthcare
Table 4.16 ADC Molecules in Clinical Development: Biotest
Table 4.17 ADC Molecules in Clinical Development: Bristol-Myers Squibb
Table 4.18 ADC Molecules in Clinical Development: Stem CentRx
Table 4.19 ADC Molecules in Clinical Development: VIVENTIA Biotechnologies
Table 4.20 ADC Molecules in Preclinical Development: Ambrx
Table 4.21 ADC Molecules in Preclinical Development: Oxford BioTherapeutics
Table 4.22 ADC Molecules in Preclinical Development: Novartis
Table 4.23 ADC Molecules in Preclinical Development: Roche / Genentech
Table 4.24 ADC Molecules in Preclinical Development: Sanofi Aventis
Table 4.25 ADC Molecules in Preclinical Development: Amgen
Table 4.26 ADC Molecules in Preclinical Development: Synthon
Table 4.27 ADC Molecules in Preclinical Development: AbbVie
Table 4.28 ADC Molecules in Preclinical Development: AbGenomics
Table 4.29 ADC Molecules in Preclinical Development: ADC Therapeutics
Table 4.30 ADC Molecules in Preclinical Development: Affinicon
Table 4.31 ADC Molecules in Preclinical Development: Allozyn
Table 4.32 ADC Molecules in Preclinical Development: Avid Bioscics
Table 4.33 ADC Molecules in Preclinical Development: Astellas / Agensys
Table 4.34 ADC Molecules in Preclinical Development: Bayer
Table 4.35 ADC Molecules in Preclinical Development: Bristol Myers Squibb
Table 4.36 ADC Molecules in Preclinical Development: Celldex Therapeutics
Table 4.37 ADC Molecules in Preclinical Development: Daiichi Sankyo
Table 4.38 ADC Molecules in Preclinical Development: Eli Lilly
Table 4.39 ADC Molecules in Preclinical Development: Endo Pharmaceuticals
Table 4.40 ADC Molecules in Preclinical Development: Esperance Pharmaceuticals
Table 4.41 ADC Molecules in Preclinical Development: GSK
Table 4.42 ADC Molecules in Preclinical Development: Intellect Neurosciences
Table 4.43 ADC Molecules in Preclinical Development: Merck
Table 4.44 ADC Molecules in Preclinical Development: ImmunoGen
Table 4.45 ADC Molecules in Preclinical Development: Heidelberg Pharma
Table 4.46 ADC Molecules in Preclinical Development: Seattle Genetics
Table 4.47 ADC Molecules in Preclinical Development: National Research Council, Canada
Table 4.48 ADC Molecules in Preclinical Development: Pfizer
Table 4.49 ADC Molecules in Preclinical Development: Phiochem
Table 4.50 ADC Molecules in Preclinical Development: CytomX Therapeutics
Table 4.51 Commonly Used Cytotoxins for ADC Therapeutics
Table 4.52 OEL Bands, Safebridge Consultants
Table 4.53 Pipeline ADCs Using Valine-Citrulline Peptide Linker
Table 4.54 Pipeline ADCs Using Hindered Disulphide Linker
Table 4.55 Pipeline ADCs Using Hydrazone Linker
Table 4.56 Pipeline ADCs Using Maleimidocaproyl Linker
Table 4.57 Pipeline ADCs Using Thioether Linker
Table 4.58 Pipeline ADCs Using Protease Cleavable Peptide Linker
Table 4.59 Pipeline ADCs Using Other Non-Cleavable Linker
Table 4.60 Pipeline ADCs Using Furin Cleavable Peptide Linker
Table 5.1 Current Development Phase and Expected Launch Year of ADCs in Clinical Development (Phase II and Higher)
Scenario
Table 12.33 Inotuzumab Ozogamicin / CMC-544 Market (USD Million), Long Term Forecast: 2018-2024 (Conservative Scenario)
Table 12.34 Inotuzumab Ozogamicin / CMC-544 Market (USD Million), Long Term Forecast: 2018-2024 (Optimistic Scenario)
Table 12.35 RG7596 Market (USD Million), Long Term Forecast, 2018-2024 (Base Scenario)
Table 12.36 RG7596 Market (USD Million), Long Term Forecast, 2018-2024 (Conservative Scenario)
Table 12.37 RG7596 Market (USD Million), Long Term Forecast, 2018-2024 (Optimistic Scenario)
Table 12.38 PSMA ADC Market (USD Million), Long Term Forecast, 2019-2024 (Base Scenario)
Table 12.39 PSMA ADC Market (USD Million), Long Term Forecast, 2019-2024 (Conservative Scenario)
Table 12.40 PSMA ADC Market (USD Million), Long Term Forecast, 2019-2024 (Optimistic Scenario)
Table 12.41 SAR3419 Market (USD Million), Long Term Forecast, 2019-2024 (Base Scenario)
Table 12.42 SAR3419 Market (USD Million), Long Term Forecast, 2019-2024 (Conservative Scenario)
Table 12.43 SAR3419 Market (USD Million), Long Term Forecast, 2019-2024 (Optimistic Scenario)
Table 12.44 IMMU-130 Market (USD Million), Long Term Forecast, 2018-2024 (Base Scenario)
Table 12.45 IMMU-130 Market (USD Million), Long Term Forecast, 2018-2024 (Conservative Scenario)
Table 12.46 IMMU-130 Market (USD Million), Long Term Forecast, 2018-2024 (Optimistic Scenario)
Table 12.47 RG7599 Market (USD Million), Long Term Forecast, 2018-2024 (Base Scenario)
Table 12.48 RG7599 Market (USD Million), Long Term Forecast, 2018-2024 (Conservative Scenario)
Table 12.49 RG7599 Market (USD Million), Long Term Forecast, 2018-2024 (Optimistic Scenario)
Table 12.50 ABT-414 Market (USD Million), Long Term Forecast, 2018-2024 (Base Scenario)
Table 12.51 ABT-414 Market (USD Million), Long Term Forecast, 2018-2024 (Conservative Scenario)
Table 12.52 ABT-414 Market (USD Million), Long Term Forecast, 2018-2024 (Optimistic Scenario)
Table 12.53 Seattle Genetics: Sales Performance (USD Million), 2011-2014 Q1
Table 12.54 Pfizer Sales Performance (USD Billion), 2011 – 2014 Q1
Table 12.55 Roche Group Sales Performance (CHF Billion), 2011 – 2014 Q1
Table 12.56 Roche Group HER2 Franchise Sales Performance (CHF Million), 2013 – 2014 Q1

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/2904221/](http://www.researchandmarkets.com/reports/2904221/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024
Web Address: http://www.researchandmarkets.com/reports/2904221/
Office Code: SCD23GL4

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 1899</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 3999</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6499</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ________________________________________________________________
City: ________________________________________________________________
Postal / Zip Code: ________________________________________________________
Country: ______________________________________________________________
Phone Number: __________________________________________________________
Fax Number: ____________________________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:  You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check:  Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:  Please transfer funds to:
Account number  833 130 83
Sort code  98-53-30
Swift code  ULSBIE2D
IBAN number  IE78ULSB98533083313083
Bank Address  Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World